{
    "clinical_study": {
        "@rank": "116119", 
        "arm_group": [
            {
                "arm_group_label": "RXI-109 Cohort 1", 
                "arm_group_type": "Experimental", 
                "description": "Treatment with RXI-109 at the site of one excised keloid and a placebo at the site of a second excised keloid. Dosing to begin at the time of surgery."
            }, 
            {
                "arm_group_label": "RXI-109 Cohort 2", 
                "arm_group_type": "Experimental", 
                "description": "Treatment with RXI-109 at the site of one excised keloid and a placebo at the site of a second excised keloid. Dosing to begin two weeks after surgery."
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the effectiveness of RXI-109 in reducing the recurrence of keloid formation\n      following elective keloid excision."
        }, 
        "brief_title": "A Multi-Center, Prospective, Randomized, Single-Blind, Within-Subject Controlled, Phase 2a Study to Evaluate the Effectiveness and Safety of RXI-109 on the Outcome of Keloid Excision Surgery in Healthy Adults", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Keloid", 
        "condition_browse": {
            "mesh_term": "Keloid"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adults, 21-55 years of age.\n\n          -  Two keloids of approximately similar size and anatomical location on the earlobe,\n             neck, or torso.\n\n          -  Keloids to be excised must have been present for > 1 year.\n\n        Exclusion Criteria:\n\n          -  Use of tobacco or nicotine-containing products\n\n          -  Pregnant or lactating\n\n          -  Post-menopausal or full hysterectomy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02079168", 
            "org_study_id": "RXI-109-1401"
        }, 
        "intervention": [
            {
                "arm_group_label": "RXI-109 Cohort 1", 
                "description": "Intradermal administration of RXI-109 at the site of one excised keloid and a placebo comparator at the site of a second excised keloid. Dosing to begin at the time of surgery.", 
                "intervention_name": "RXI-109 Cohort 1", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "RXI-109 Cohort 2", 
                "description": "Intradermal administration of RXI-109 at the site of one excised keloid and a placebo comparator at the site of a second excised keloid. Dosing to begin two weeks after surgery.", 
                "intervention_name": "RXI-109 Cohort 2", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Keloid", 
            "Cicatrix", 
            "Keloid prevention", 
            "Keloid revision/excision", 
            "Keloidectomy"
        ], 
        "lastchanged_date": "April 21, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "St. Louis", 
                    "country": "United States", 
                    "state": "Missouri", 
                    "zip": "63141"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multi-Center, Prospective, Randomized, Single-Blind, Within-Subject Controlled, Phase 2a Study to Evaluate the Effectiveness and Safety of RXI-109 on the Outcome of Keloid Excision Surgery in Healthy Adults", 
        "overall_contact": {
            "email": "clinicaloperations@rxipharma.com", 
            "last_name": "Manager, Clinical Operations"
        }, 
        "overall_official": {
            "affiliation": "RXi Pharmaceuticals", 
            "last_name": "Pamela Pavco, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To evaluate the effectiveness of RXI-109 in reducing the recurrence of keloid formation following elective keloid excision", 
            "measure": "Reduction in the recurrence of a keloid after keloid excision", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02079168"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "To assess severity and frequency of reported adverse events and clinically-relevant changes in laboratory testing after elective excision of a keloid", 
            "measure": "Safety of RXI-109", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "source": "RXi Pharmaceuticals, Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "RXi Pharmaceuticals, Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}